Finance

Lists
Why is GANX up 5.83%?
Dive Deeper
GANX:NASDAQ
Gain Therapeutics Inc
US$1.09
+5.83%
(+0.060) 1D
US$1.09
0.00% (0.00)
After hours
Closed: ኖቬም 9, 4:00:00 ከሰዓት ጂ ኤም ቲ-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GANX...
Open
US$1.02
High
US$1.12
Low
US$1.00
Mkt. cap
47.57 ሚ
Avg. vol.
590.19 ሺ
Volume
8.00
52-wk high
US$4.34
52-wk low
US$0.94
EPS
-US$0.51
Beta
0.29
Shares outstanding
43.64 ሚ
No. of employees
21
Open
US$1.02
High
US$1.12
Low
US$1.00
Mkt. cap
47.57 ሚ
Avg. vol.
590.19 ሺ
Volume
8.00
52-wk high
US$4.34
52-wk low
US$0.94
EPS
-US$0.51
Beta
0.29
Shares outstanding
43.64 ሚ
No. of employees
21
News stories
From web sources and news partners
BigGo Finance
BigGo Finance
·
ከ1 ሰዓት በፊት
NYSE's Tokenized Equity Market Adopts Avalanche for Clearing Infrastructure, Sending AVAX Soaring
The Daily News | Texas' Oldest Newspaper
The Daily News | Texas' Oldest Newspaper
·
ከ11 ደቂቃዎች በፊት
Traders work on the floor of the NYSE in New York
The Motley Fool
The Motley Fool
·
ከ40 ደቂቃዎች በፊት
2 Vanguard Index Funds to Buy Now to Beat the S&P 500 in the Next Year, According to Wall Street
Bloomberg.com
Bloomberg.com
·
ከ1 ሰዓት በፊት
Asian Stocks to Rally on US Tech Surge, Oil Slump: Markets Wrap
About Gain Therapeutics Inc
CEO-
Employees21
Founded2017
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitegaintherapeutics.com
Analyst ratings
Based on 5 analysts giving stock ratings to GANX in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for GANX in the last 3 months.
Highest
Current US$1.09
US$8.00 (+633.94%)
Average
US$7.20 (+560.55%)
Lowest
US$5.00 (+358.72%)
Analyst
Recommendation
Action
Price target
Projected
Date
Thomas Shrader
BTIG
Buy
Maintained
US$5.00
+358.7%
10/05/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
US$8.00
+633.9%
10/05/2026
Jason McCarthy
Maxim Group
Buy
Maintained
US$7.00
+542.2%
10/01/2026
Boobalan Pachaiyappan
Roth MKM
Buy
Maintained
US$8.00
+633.9%
08/18/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
US$8.00
+633.9%
08/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ሴፕቴ 2025
ዲሴም 2025
ማርች 2026
ጁን 2026
Revenue
-
-
-
-
Cost of goods sold
2.81 ሚ
2.32 ሚ
2.74 ሚ
2.12 ሚ
Cost of revenue
2.81 ሚ
2.32 ሚ
2.74 ሚ
2.12 ሚ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.98 ሚ
2.15 ሚ
2.61 ሚ
2.56 ሚ
Operating expense
1.98 ሚ
2.15 ሚ
2.61 ሚ
2.56 ሚ
Total operating expenses
4.79 ሚ
4.47 ሚ
5.35 ሚ
4.68 ሚ
Operating income
-4.79 ሚ
-4.47 ሚ
-5.35 ሚ
-4.68 ሚ
Other non operating income
-
-
-
-
EBT including unusual items
-4.74 ሚ
-4.47 ሚ
-5.43 ሚ
-4.57 ሚ
EBT excluding unusual items
-4.74 ሚ
-4.47 ሚ
-5.43 ሚ
-4.57 ሚ
Income tax expense
549.29 ሺ
70.12 ሺ
183.07 ሺ
104.07 ሺ
Effective tax rate
-11.60%
-1.57%
-3.37%
-2.28%
Other operating expenses
-
-
-
-
Net income
-5.28 ሚ
-4.54 ሚ
-5.61 ሚ
-4.68 ሚ
Net profit margin
-
-
-
-
Earnings per share
-0.15
-0.11
-0.13
-0.11
Interest and investment income
83.30 ሺ
88.58 ሺ
93.34 ሺ
60.73 ሺ
Interest expense
-
-
-
-
Net interest expenses
83.30 ሺ
88.58 ሺ
93.34 ሺ
60.73 ሺ
Depreciation and amortization charges
-
-
-
-
EBITDA
-4.78 ሚ
-4.46 ሚ
-5.34 ሚ
-4.67 ሚ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google መተግበሪያዎች